Navigation Links
S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
Date:12/10/2007

Data Presented on Three S*BIO Compounds at The American Society of

Hematology 2007

SINGAPORE, Dec. 10 /PRNewswire/ -- S*BIO Pte Ltd today announced the data presentation on its most advanced compounds at The American Society of Hematology 49th Annual Meeting and Exposition in Atlanta, Georgia. An oral presentation made on its novel and selective JAK2 inhibitor SB1518 highlighted the therapeutic potential of SB1518 for the treatment of myeloproliferative disorders.

In addition, a poster was presented on S*BIO's orally-active "best-in- class" HDAC inhibitor SB939 detailing its therapeutic potential for the treatment of hematological malignancies while a poster on S*BIO's novel kinase inhibitor SB1317 showed data for the potential treatment of acute leukemias.

"We are pleased to announce data for the first time on our JAK2 inhibitor, SB1518, and its potential treatment of myeloproliferative disorders, an area of great unmet medical need," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "We are currently conducting Phase I clinical trials for SB939 in Canada and Singapore, and expect the initiation of Phase I trials in various centers in the U.S. We are also delighted to report data on our Flt3-CDK inhibitor, SB1317. The data presented clearly demonstrate the strength and diversity of S*BIO's pipeline and validate our target-driven approach in developing 'best-in-class' and 'first-in-class' drugs."

Oral Presentation (Session: Molecular Pharmacology -- Novel Therapies I)

SB1518: A potent and orally-active JAK2 Inhibitor for the treatment of myeloproliferative disorders

SB1518, a potent ATP-competitive inhibitor of both JAK2 kinase, and its JAK2V617F mutant, demonstrated therapeutic potential for the treatment of myeloproliferative disorders caused by aberrant JAK2 signaling. JAK2 is the most common mutated gene in bcr-abl-negative chronic myeloproliferative disorders (MPDs).

Poster No. 757

SB939: A potent and orally-active HDAC inhibitor for the treatment of hematological malignancies

SB939, a novel histone deacetylase HDAC inhibitor with improved metabolic, pharmacokinetic and pharmacological properties compared to other HDAC inhibitors, is currently in Phase I clinical trials, and has demonstrated potential for the treatment of various types of hematological malignancies.

Poster No. 747

SB1317, a potent and orally-active FLT3-CDK inhibitor with high anti-tumor efficacy in models of hematological malignancies

SB1317, a novel potent inhibitor of FLT3 kinase and CDKs 1, 2 and 9, demonstrated therapeutic potential for the treatment of hematological malignancies. FLT3 is the most common mutated gene in acute myeloid leukemia

(AML), and CDK1, 2, and 9 are well-established anti-cancer targets due to their direct role in cell cycle control.

About S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, has entered the clinic in 2Q 2007. It recently announced that a second compound, SB1518, would enter the clinic in 1H 2008 and that a third compound, SB1317, is in pre-clinical development.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong linkages with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital, Novartis Bioventures and other international funds. More information about S*BIO can be found at http://www.sbio.com.

S*BIO Pte Ltd:

Stephen Keith Rhind, Ph.D.

Senior Vice President, Corporate Development

Tel: +65 6827 5000 (Singapore)

Stephen_rhind@sbio.com

Russo Partners:

Tony Russo +1 212-845-4251

Tony.Russo@russopartnersllc.com

Andreas Marathovouniotis +1 212-845-4253

Andreas.Marathis@russopartnersllc.com


'/>"/>
SOURCE S*BIO Pte Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
4. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
5. Silencing small but mighty cancer inhibitors
6. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
7. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
8. Highmarks Hospital Pay-for-Performance Program Demonstrates Impressive Results
9. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
10. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
11. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2017)... ... ... Swissray is pleased to announce the release of the ELITE DXA, a new bone ... scan window, which is more than double that of existing bone densitometers. Historically, subjects ... an accurate total body bone density or body composition study. The ELITE DXA ...
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its NAEMT ... by providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned ... education developed in cooperation with the American College of Surgeons to promote critical ...
(Date:3/24/2017)... NY (PRWEB) , ... March 24, 2017 , ... ... scale; from third world countries to hospitals in the United States, it’s a ... conversation on the current obstacles facing infection prevention and offers strategies for the ...
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management Association (RBMA) ... awards, now in their 12th year, are among the most prestigious in radiology marketing ... the awards were retooled to recognize achievements in both large budget (over $5,000) and ...
(Date:3/24/2017)... TX (PRWEB) , ... March 24, 2017 , ... ... clinic which can be found at 9618 Huebner Road. The clinic is the group’s ... OCS, Clinic Director, and Dr. Ali Higgins, PT, will provide care from the clinic, ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... in Drug Discovery and Diagnostics, 2017 - 2035" report to ... The ... current landscape and future outlook of the growing market of deep ... data revolution, deep learning algorithms have emerged as a novel solution ...
(Date:3/24/2017)... 24, 2017 Today Stock-Callers.com have issued ... are: Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards ... SSH ). These companies are part of the Healthcare ... Thursday, March 23 rd , 2017, with the NYSE Health ... health care companies in the S&P 500 were down about ...
(Date:3/24/2017)... INDIANAPOLIS , March 24, 2017  Eli ... today announced plans to invest $850 million in ... span facilities across its U.S. enterprise, including research ... The investments are being driven by demand for ... of potential medicines in development targeting cancer, pain, ...
Breaking Medicine Technology: